Erasca continues ascent after cancer therapy co's upsized $225 mln stock offering

Erasca ERAS.O shares up 3.1% before the bell to $10.36 after above-target $225 mln equity raise

ERAS shares poised to rise for 7th straight session, if gains hold

San Diego, California-based precision oncology co late Weds announced pricing 22.5 mln shares at $10

ERAS shares on Weds closed up 2.5% at $10.05 after co late Tues unveiled planned $150 mln stock offering

Co intends to use net offering proceeds to help fund R&D of its product candidates and other development programs, and working capital and other general corporate purposes

JP Morgan, Morgan Stanley, Jefferies and Evercore joint bookrunners

Through Weds close, ERAS shares have surged 170% to start 2026. Stock up more than five-fold over the past 12 months

Avg rating among 11 analysts is "buy"; median PT $7.50, according to LSEG data